Physiological inhibitors of Wnt signaling

European Journal of Haematology

Volumn 86, Issue 6, 2011, Pages 453-465

  Filipovich, Alexandra ^a   Gehrke, Iris ^a   Poll Wolbeck, Simon J ^a   Kreuzer, Karl Anton ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antagonist; Cancer; Inhibitor; Wnt

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; DISHEVELLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; KLOTHO PROTEIN; LIGAND; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; SCLEROSTIN; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETED FRIZZLED RELATED PROTEIN 5; SERINE PROTEINASE INHIBITOR; WNT PROTEIN;

HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BETA CATENIN; HUMANS; LDL-RECEPTOR RELATED PROTEINS; LIGANDS; MODELS, BIOLOGICAL; PHOSPHOPROTEINS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 79956023778     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01592.x     Document Type: Review

References (151)

1. Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007;13:4042-5.
2. Wang YQ. Wnt/Planar cell polarity signaling: a new paradigm for cancer therapy. Mol Cancer Ther 2009;8:2103-9.
3. Okoye U, Malbon C, Wang Hy. Wnt and Frizzled RNA expression in human mesenchymal and embryonic (H7) stem cells. J Mol Signal 2008;3:16.
4. Sethi JK, Vidal-Puig A. Wnt signalling and the control of cellular metabolism. Biochem J 2010;427:1-17.
5. Murdoch B, Chadwick K, Martin M, Shojaei F, Shah KV, Gallacher L, Moon RT, Bhatia M. Wnt-5A augments repopulating capacity and primitive hematopoietic development of human blood stem cells in vivo. Proc Natl Acad Sci U S A 2003;100:3422-7.
6. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003;423:409-14.
7. Cobas M, Wilson A, Ernst B, Mancini JC, MacDonald HR, Kemler R, Radtke F. Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. J Exp Med 2004;199:221-9.
8. Zhao JS, Kim KA, Abo A. Tipping the balance: modulating the Wnt pathway for tissue repair. Trends Biotechnol 2009;27:131-6.
9. Bhat RA, Stauffer B, Komm BS, Bodine PVN. Structure-function analysis of secreted frizzled-related protein-1 for its Wnt antagonist function. J Cell Biochem 2007;102:1519-28.
10. Dann CE, Hsieh JC, Rattner A, Sharma D, Nathans J, Leahy DJ. Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich domains. Nature 2001;412:86-90.
11. Lopez-Rios J, Esteve P, Ruiz JM, Bovolenta P. The netrin-related domain of Sfrp1 interacts with Wnt ligands and antagonizes their activity in the anterior neural plate. Neural Dev 2008;3:19-37.
12. Esteve P, Bovolenta P. The advantages and disadvantages of Sfrp1 and Sfrp2 expression in pathological events. Tohoku J Exp Med 2010;221:11-7.
13. Veeck J, Geisler C, Noetzel E, Alkaya S, Hartmann A, Knuchel R, Dahl E. Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis 2008;29:991-8.
14. Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knuchel R, Dahl E. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Mol Cancer 2008;7:83-101.
15. Huang ZH, Li LH, Wang JF. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 2007;52:2287-91.
16. Bodine PVN, Stauffer B, Ponce-de-Leon H, et al. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone 2009;44:1063-8.
17. Barandon L, Couffinhal T, Ezan J, Dufourcq P, Costet P, Alzieu P, Leroux L, Moreau C, Dare D, Duplaa C. Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation 2003;108:2282-9.
18. Kuroo M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51.
19. Liu HJ, Fergusson MM, Castilho RM, et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007;317:803-6.
20. Lee J, Jeong DJ, Kim J, et al. The anti-aging gene KLOTHO is a novel target for epigenetic silencing in human cervical carcinoma. Mol Cancer 2010;9:109-18.
21. Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999;398:431-6.
22. Patthy L. The WIF module. Trends Biochem Sci 2000;25:12-3.
23. Liepinsh E, Banyai L, Patthy L, Otting G. NMR structure of the WIF domain of the human Wnt-inhibitory factor-1. J Mol Biol 2006;357:942-50.
24. Surmann-Schmitt C, Widmann N, Dietz U, et al. Wif-1 is expressed at cartilage-mesenchyme interfaces and impedes Wnt3a-mediated inhibition of chondrogenesis. J Cell Sci 2009;122:3627-37.
25. Licchesi JDF, Van Neste L, Tiwari VK, Cope L, Lin X, Baylin SB, Herman JG. Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc. Oncogene 2010;29:5923-34.
26. Yang ZAY, Wang Y, Fang JS, Chen FH, Liu JF, Wu J, Wang YJ, Song T, Zeng FY, Rao YH. Downregulation of WIF-1 by hypermethylation in astrocytomas. Acta Biochim Biophys Sin 2010;42:418-25.
27. Deng Y, Yu B, Cheng Q, et al. Epigenetic silencing of WIF-1 in hepatocellular carcinomas. J Cancer Res Clin Oncol 2010;136:1161-7.
28. He BA, Reguart N, You L, Mazieres J, Xu ZD, Lee AY, Mikami I, McCormick F, Jablons DM. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005;24:3054-8.
29. Li YH, Lu WY, King TD, Liu CC, Bijur GN, Bu GJ. Dkk1 stabilizes Wnt co-receptor LRP6: implication for Wnt ligand-induced LRP6 down-regulation. PLoS ONE 2010;5:e11014.
30. Hassler C, Cruciat CM, Huang YL, Kuriyama S, Mayor R, Niehrs C. Kremen is required for neural crest induction in Xenopus and promotes LRP6-mediated Wnt signaling. Development 2007;134:4255-63.
31. Weidauer SE, Schmieder P, Beerbaum M, Schmitz W, Oschkinat H, Mueller TD. NMR structure of the Wnt modulator protein Sclerostin. Biochem Biophys Res Commun 2009;380:160-5.
32. Semenov M, Tamai K, Xi H. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005;280:26770-5.
33. Li XF, Zhang YZ, Kang HS, Liu WZ, Liu P, Zhang JG, Harris SE, Wu DQ. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280:19883-7.
34. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004;199:805-14.
35. van Bezooijen RL, Bronckers AL, Gortzak RA, et al. Sclerostin in mineralized matrices and van Buchem disease. J Dent Res 2009;88:569-74.
36. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2010;1:19-26.
37. Veverka V, Henry AJ, Slocombe PM, et al. Characterization of the structural features and interactions of sclerostin molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 2009;284:10890-900.
38. Hsieh JC, Lee L, Zhang LQ, Wefer S, Brown K, DeRossi C, Wines ME, Rosenquist T, Holdener BC. Mesd encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity. Cell 2003;112:355-67.
39. Herz J, Marschang P. Coaxing the LDL receptor family into the fold. Cell 2003;112:289-92.
40. Li YH, Chen JL, Lu WY, McCormick LM, Wang JJ, Bu GJ. Mesd binds to mature LDL-receptor-related protein-6 and antagonizes ligand binding. J Cell Sci 2005;118:5305-14.
41. Liu CC, Pearson C, Bu GJ. Cooperative folding and ligand-BINDING properties of LRP6 beta-propeller domains. J Biol Chem 2009;284:15299-307.
42. Lu WY, Liu CC, Thottassery JV, Bu GJ, Li YH. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells. Biochemistry 2010;49:4635-43.
43. Murrills RJ, Matteo JJ, Bhat BM, Coleburn VE, Allen KM, Chen W, Damagnez V, Bhat RA, Bex FJ, Bodine PVN. A cell-based Dkk1 binding assay reveals roles for extracellular domains of LRP5 in Dkk1 interaction and highlights differences between wild-type and the high bone mass mutant LRP5(G171V). J Cell Biochem 2009;108:1066-75.
44. Liu CC, Prior J, Piwnica-Worms D, Bu G. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci USA 2010;107:5136-41.
45. Zhang B, Abreu JG, Zhou K, Chen Y, Hu Y, Zhou T, He X, Ma JX. Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family. Proc Natl Acad Sci USA 2010;107:6900-5.
46. Gao G, Shao C, Zhang SX, Dudley A, Fant J, Ma JX. Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage. Diabetologia 2003;46:689-98.
47. Chen Y, Hu Y, Zhou T, Zhou KK, Mott R, Wu MY, Boulton M, Lyons TJ, Gao GQ, Ma JX. Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol 2009;175:2676-85.
48. Zirn B, Samans B, Wittmann S, Pietsch T, Leuschner I, Graf N, Gessler M. Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes Chromosom Cancer 2006;45:565-74.
49. Shimomura Y, Agalliu D, Vonica A, et al. APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex. Nature 2010;464:1043-U109.
50. Wang K, Zhang YZ, Li XF, Chen LJ, Wang H, Wu JG, Zheng J, Wu DQ. Characterization of the Kremen-binding site on Dkk1 and elucidation of the role of Kremen in Dkk-mediated Wnt antagonism. J Biol Chem 2008;283:23371-5.
51. Semenov MV, Tamai K, Brott BK, Kuhl M, Sokol S, He X. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol 2001;11:951-61.
52. Mao BY, Wu W, Davidson G, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 2002;417:664-7.
53. Semenov MV, Zhang X, He X. DKK1 antagonizes Wnt signaling without promotion of LRP6 internalization and degradation. J Biol Chem 2008;283:21427-32.
54. Gotze S, Wolter M, Reifenberger G, Muller O, Sievers S. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer 2010;126:2584-93.
55. Filipovich A, Gandhirajan RK, Gehrke I, Poll-Wolbeck SJ, Kreuzer KA. Evidence for non-functional Dickkopf-1 (DKK-1) signaling in chronic lymphocytic leukemia (CLL). Eur J Haematol 2010;85:309-13.
56. Bjorklund P, Svedlund J, Olsson AK, Akerstrom G, Westin G. The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS ONE 2009;4:e4243.
57. Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA, Abdiche Y, Stone DM, Paralkar VM. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 2010;333:2-13.
58. Wang XH, Adhikari N, Li QL, Hall JL. LDL receptor-related protein LRP6 regulates proliferation and survival through the Wnt cascade in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2004;287:H2376-83.
59. Wu W, Glinka A, Delius H, Niehrs C. Mutual antagonism between dickkopf1 and dickkopf2 regulates Wnt/beta-catenin signalling. Curr Biol 2000;10:1611-4.
60. Nakamura REI, Hackam AS. Analysis of Dickkopf3 interactions with Wnt signaling receptors. Growth Factors 2000;28:232-42.
61. El Nakamura R, Hunter DD, Yi H, Brunken WJ, Hackam AS. Identification of two novel activities of the Wnt signaling regulator Dickkopf 3 and characterization of its expression in the mouse retina. BMC Cell Biol 2007;8:52-61.
62. Mao BY, Niehrs C. Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling. Gene 2003;302:179-83.
63. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 2006;4:570-82.
64. Nishita M, Itsukushima S, Nomachi A, Endo M, Wang ZC, Inaba D, Qiao S, Takada S, Kikuchi A, Minami Y. Ror2/Frizzled complex mediates Wnt5a-induced AP-1 activation by regulating dishevelled polymerization. Mol Cell Biol 2010;30:3610-9.
65. James V, Zhang YN, Foxler DE, et al. LIM-domain proteins, LIMD1, Ajuba, and WTIP are required for microRNA-mediated gene silencing. Proc Natl Acad Sci USA 2010;107:12499-504.
66. van Wijk NV, Witte F, Feike AC, Schambony A, Birchmeier W, Mundlos S, Stricker S. The LIM domain protein Wtip interacts with the receptor tyrosine kinase Ror2 and inhibits canonical Wnt signalling. Biochem Biophys Res Commun 2009;390:211-6.
67. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009;156:885-98.
68. Kanungo J, Pratt SJ, Marie H, Longmore GD. Ajuba, a cytosolic LIM protein, shuttles into the nucleus and affects embryonal cell proliferation and fate decisions. Mol Biol Cell 2000;11:3299-313.
69. Abe Y, Ohsugi M, Haraguchi K, Fujimoto J, Yamamoto T. LATS2-Ajuba complex regulates gamma-tubulin recruitment to centrosomes and spindle organization during mitosis. FEBS Lett 2006;580:782-8.
70. Marie H, Pratt SJ, Betson M, et al. The LIM protein Ajuba is recruited to cadherin-dependent cell junctions through an association with alpha-catenin. J Biol Chem 2003;278:1220-8.
71. Haraguchi K, Ohsugi M, Abe Y, Semba K, Akiyama T, Yamamoto T. Ajuba negatively regulates the Wnt signaling pathway by promoting GSK-3 beta-mediated phosphorylation of beta-catenin. Oncogene 2008;27:274-84.
72. Lechward K, Sugajska E, de Baere I, Goris J, Hemmings BA, Zolnierowicz S. Interaction of nucleoredoxin with protein phosphatase 2A. FEBS Lett 2006;580:3631-7.
73. Funato Y, Michiue T, Terabayashi T, Yukita A, Danno H, Asashima M, Miki H. Nucleoredoxin regulates the Wnt/planar cell polarity pathway in Xenopus. Genes Cells 2008;13:965-75.
74. Funato Y, Michiue T, Asashima M, Miki H. The thioredoxin-related redox-regulating protein nucleoredoxin inhibits Wnt-beta-catenin signalling through dishevelled. Nat Cell Biol 2006;8:501-U135.
75. Zeng WL, Wharton KA, Mack JA, Wang K, Gadbaw M, Suyama K, Klein PS, Scott MP. Naked cuticle encodes an inducible antagonist of Wnt signalling. Nature 2000;403:789-95.
76. Wharton KA, Zimmermann G, Rousset R, Scott MP. Vertebrate proteins related to Drosophila naked cuticle bind dishevelled and antagonize Wnt signaling. Dev Biol 2001;234:93-106.
77. Yan D, Wallingford JB, Sun TQ, Nelson AM, Sakanaka C, Reinhard C, Harland RM, Fantl WJ, Williams LT. Cell autonomous regulation of multiple dishevelled-dependent pathways by mammalian Nkd. Proc Natl Acad Sci U S A 2001;98:3802-7.
78. Van Raay TJ, Coffey RJ, Soinica-Krezel L. Zebrafish naked1 and naked2 antagonize both canonical and non-canonical wnt signaling. Dev Biol 2007;309:151-68.
79. Creyghton MP, Roel G, Eichhorn PJA, Hijmans EM, Maurer I, Destree O, Bernards R. PR72, a novel regulator of Wnt signaling required for naked cuticle function. Genes Dev 2005;19:376-86.
80. Waldrop S, Chan CC, Cagatay T, et al. An unconventional nuclear localization motif is crucial for function of the Drosophila Wnt/wingless antagonist naked cuticle. Genetics 2006;174:331-48.
81. Chan CC, Zhang S, Cagatay T, Wharton KA. Cell-autonomous, myristyl-independent activity of the Drosophila Wnt/wingless antagonist Naked cuticle (Nkd). Dev Biol 2007;311:538-53.
82. Chan CC, Zhang S, Rousset R, Wharton KA. Drosophila Naked cuticle (Nkd) engages the nuclear import adaptor Importin-alpha 3 to antagonize Wnt/beta-catenin signaling. Dev Biol 2008;318:17-28.
83. Koch A, Waha A, Hartmann W, Hrychyk A, Schuller U, Waha A, Wharton KA, Fuchs SY, von Schweinitz D, Pietsch T. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res 2005;11:4295-304.
84. Guo JH, Cagatay T, Zhou GJ, et al. Mutations in the human naked cuticle homolog NKD1 found in colorectal cancer alter Wnt/Dvl/beta-catenin signaling. PLoS ONE 2009;4:e7982.
85. Sun TQ, Lu BW, Feng JJ, Reinhard C, Jan YN, Fantl WJ, Williams LT. PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt signalling. Nat Cell Biol 2001;3:628-36.
86. Grisaru-Granovsky S, Maoz M, Barzilay O, Yin YJ, Prus D, Bar-Shavit R. Protease activated receptor-1, PAR1, promotes placenta trophoblast invasion and beta-catenin stabilization. J Cell Physiol 2009;218:512-21.
87. Bohring A, Stamm T, Spaich C, et al. WNT10A mutations are a frequent cause of a broad spectrum of ectodermal dysplasias with sex-biased manifestation pattern in heterozygotes. Am J Hum Genet 2009;85:97-105.
88. Kim MS, Yoon SK, Bollig F, et al. A novel wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway. J Biol Chem 2010;285:14585-93.
89. Andersson T, Sodersten E, Duckworth JK, Cascante A, Fritz N, Sacchetti P, Cervenka I, Bryja V, Hermanson O. CXXC5 Is a Novel BMP4-regulated modulator of Wnt signaling in neural stem cells. J Biol Chem 2009;284:3672-81.
90. Hino SI, Kishida S, Michiue T, Fukui A, Sakamoto I, Takada S, Asashima M, Kikuchi A. Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein. Mol Cell Biol 2001;21:330-42.
91. London TBC, Lee HJ, Shao YM, Zheng J. Interaction between the internal motif KTXXXI of Idax and mDvl PDZ domain. Biochem Biophys Res Commun 2004;322:326-32.
92. Kojima T, Shimazui T, Hinotsu S, et al. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling. Oncogene 2009;28:297-305.
93. Miyoshi H, Deguchi A, Nakau M, Kojima Y, Mori A, Oshima M, Aoki M, Taketo MM. Hepatocellular carcinoma development induced by conditional beta-catenin activation in Lkb1+/- mice. Cancer Sci 2009;100:2046-53.
94. Graham TA. The crystal structure of the beta-catenin/ICAT complex reveals the inhibitory mechanism of ICAT. Mol Cell 2002;10:563-71.
95. Tago K, Nakamura T, Nishita M, et al. Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Dev 2000;14:1741-9.
96. Daniels DL, Weis WI. ICAT inhibits beta-catenin binding to Tcf/Lef-family transcription factors and the general coactivator p300 using independent structural modules. Mol Cell 2002;10:573-84.
97. Gottardi CJ, Gumbiner BM. Role for ICAT in beta-catenin-dependent nuclear signaling and cadherin functions. Am J Physiol Cell Physiol 2004;286:C747-56.
98. Takemaru KI, Yamaguchi S, Lee YS, Zhang Y, Carthew RW, Moon RT. Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless pathway. Nature 2003;422:905-9.
99. Xing Y, Takemaru KI, Liu J, Berndt JD, Zheng JJ, Moon RT, Xu WQ. Crystal structure of a full-length beta-catenin. Structure 2008;16:478-87.
100. Mofunanya A, Li FQ, Hsieh JC, Takemaru KI. Chibby forms a homodimer through a heptad repeat of leucine residues in its C-terminal coiled-coil motif. BMC Mol Biol 2009;10:41-55.
101. Li FQ, Mofunanya A, Harris K, Takemaru KI. Chibby cooperates with 14-3-3 to regulate beta-catenin subcellular distribution and signaling activity. J Cell Biol 2008;7:1141-54.
102. Li FQ, Mofunanya A, Fischer V, Hall J, Takemaru KI. Nuclear-cytoplasmic shuttling of chibby controls beta-catenin signaling. Mol Biol Cell 2010;21:311-22.
103. Singh AM, Li FQ, Hamazaki T, Kasahara H, Takemaru KI, Terada N. Chibby, an antagonist of the Wnt/beta-catenin pathway, facilitates cardiomyocyte differentiation of murine embryonic stem cells. Circulation 2007;115:617-26.
104. Li FQ, Singh AM, Mofunanya A, Love D, Terada N, Moon RT, Takemaru KI. Chibby promotes adipocyte differentiation through inhibition of beta-catenin signaling. Mol Cell Biol 2007;27:4347-54.
105. Schuierer MM, Graf E, Takemaru KI, Dietmaier W, Bosserhoff AK. Reduced expression of beta-catenin inhibitor Chibby in colon carcinoma cell lines. World J Gastroenterol 2006;12:1529-35.
106. Sakamoto I, Kishida S, Fukui A, Kishida M, Yamamoto H, Hino S, Michiue T, Takada S, Asashima M, Kikuchi A. A novel beta-catenin-binding protein inhibits beta-catenin-dependent Tcf activation and axis formation. J Biol Chem 2000;275:32871-8.
107. Kobayashi M, Kishida S, Fukui A, Michiue T, Miyamoto Y, Okamoto T, Yoneda Y, Asashima M, Kikuchi A. Nuclear localization of Duplin, a beta-catenin-binding protein, is essential for its inhibitory activity on the Wnt signaling pathway. J Biol Chem 2002;277:5816-22.
108. Nishiyama M, Nakayama K, Tsunematsu R, Tsukiyama T, Kikuchi A, Nakayama KI. Early embryonic death in mice lacking the beta-catenin-binding protein duplin. Mol Cell Biol 2004;24:8386-94.
109. Ishitani T, Ninomiya-Tsuji J, Nagai S, et al. The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature 1999;399:798-802.
110. Yamada M, Ohnishi J, Ohkawara B, Iemura S, Satoh K, Hyodo-Miura J, Kawachi K, Natsume T, Shibuya H. NARF, an nemo-like kinase (NLK)-associated ring finger protein regulates the ubiquitylation and degradation of T cell factor/lymphoid enhancer factor (TCF/LEF). J Biol Chem 2006;281:20749-60.
111. Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J, Waterman M, Shibuya H, Moon RT, Ninomiya-Tsuji J, Matsumoto K. The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca2+ pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol 2003;23:131-9.
112. Emami KH, Brown LG, Pitts TEM, Sun XZ, Vessella RL, Corey E. Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate 2009;14:1481-92.
113. Kortenjann M, Nehls M, Smith AJH, Carsetti R, Schuler J, Kohler G, Boehm T. Abnormal bone marrow stroma in mice deficient for nemo-like kinase, Nlk. Eur J Immunol 2001;31:3580-7.
114. Warr N, Siggers P, Bogani D, et al. Sfrp1 and Sfrp2 are required for normal male sexual development in mice. Dev Biol 2009;326:273-84.
115. Rodilla V, Villanueva A, Obrador-Hevia A, et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci USA 2009;106:6315-20.
116. Sarkar F, Li Y, Wang Z, Kong D. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer Metastasis Rev 2010;29:383-94.
117. Bjorklund P, Svedlund J, Olsson AK, Akerstrom G, Westin G. The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS ONE 2009;4:e4243.
118. Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998;58:1344-7.
119. Chim CS, Pang R, Liang R. Epigenetic dysregulation of the Wnt signalling pathway in chronic lymphocytic leukaemia. J Clin Pathol 2008;61:1214-9.
120. Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M, Terpos E. Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opin Ther Targets 2009;13:839-48.
121. Fendri A, Khabir A, Hadri-Guiga B, Sellami-Boudawara T, Daoud J, Frikha M, Ghorbel A, Gargouri A, Mokdad-Gargouri R. Epigenetic alteration of the Wnt inhibitory factor-1 promoter is common and occurs in advanced stage of tunisian nasopharyngeal carcinoma. Cancer Invest 2010;28:896-903.
122. Hoang B, Moos M, Vukicevic S, Luyten FP. Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis. J Biol Chem 1996;271:26131-7.
123. Lee CH, Hung YJ, Lin CY, Hung PH, Hung HW, Shieh YS. Loss of SFRP1 expression is associated with aberrant beta-catenin distribution and tumor progression in mucoepidermoid carcinoma of salivary glands. Ann Surg Oncol 2010;17:2237-46.
124. Feng Q, Stern JE, Hawes SE, Lu H, Jiang M, Kiviat NB. DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol 2010;88:287-92.
125. Bu XM, Zhao CH, Zhang N, Gao F, Lin S, Dai XW. Hypermethylation and aberrant expression of secreted fizzled-related protein genes in pancreatic cancer. World J Gastroenterol 2008;14:3421-4.
126. Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knuchel R, Dahl E. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Mol Cancer 2008;7:83-101.
127. Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC, Lin SP, Lin WC, Lee HY, Yu MH. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 2010;127:555-67.
128. Saini S, Liu J, Yamamura S, Majid S, Kawakami K, Hirata H, Dahiya R. Functional significance of secreted frizzled-related protein 1 in metastatic renal cell carcinomas. Cancer Res 2009;69:6815-22.
129. Hu J, Dong A, Fernandez-Ruiz V, Shan J, Kawa M, Martinez-Anso E, Prieto J, Qian C. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Cancer Res 2009;69:6951-9.
130. Hirata H, Hinoda Y, Nakajima K, et al. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer 2010;128:1793-803.
131. McCarthy HS, Marshall MJ. Dickkopf-1 as a potential therapeutic target in Paget's disease of bone. Expert Opin Ther Targets 2010;14:221-30.
132. Nakamura T, Nakamura T, Matsumoto K. The functions and possible significance of Kremen as the gatekeeper of Wnt signalling in development and pathology. J Cell Mol Med 2008;12:391-408.
133. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005;3:1800-14.
134. Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene 2008;27:4434-45.
135. Duncan MB, Kalluri R. Parstatin, a novel protease-activated receptor 1GCo derived inhibitor of angiogenesis. Mol Interv 2009;9:168-70.
136. Koyama T, Tago Ki, Nakamura T, Ohwada S, Morishita Y, Yokota J, Akiyama T. Mutation and expression of the beta-catenin-interacting protein ICAT in human colorectal tumors. Jpn J Clin Oncol 2002;32:358-62.
137. Renstrom J, Istvanffy R, Gauthier K, et al. Secreted frizzled-related protein 1 extrinsically regulates cycling activity and maintenance of hematopoietic stem cells. Cell Stem Cell 2009;5:157-67.
138. Leaf I, Tennessen J, Mukhopadhyay M, Westphal H, Shawlot W. Sfrp5 is not essential for axis formation in the mouse. Genesis 2006;44:573-8.
139. Surmann-Schmitt C. Wif-1 is expressed at cartilage-mesenchyme interfaces and impedes Wnt3a-mediated inhibition of chondrogenesis. J Cell Sci 2009;122:3627-37.
140. Hsieh JC. Mesd encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity. Cell Press 2003;112:355-67.
141. Li XD, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008;23:860-9.
142. Hsieh JC. Mesd encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity. Cell Press 2003;112:355-67.
143. Shimomura Y. APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex. Nature 2010;464:1043-7.
144. Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, et al. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell 2001;1:423-34.
145. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R. Wt-1 is required for early kidney development. Cell 1993;74:679-91.
146. Missler M, Zhang WQ, Rohlmann A, Kattenstroth G, Hammer RE, Gottmann K, Sudhof TC. alpha-neurexins couple Ca2+ channels to synaptic vesicle exocytosis. Nature 2003;423:939-48.
147. Zhang S, Cagatay T, Amanai M, Zhang M, Kline J, Castrillon DH, Ashfaq R, Oz OK, Wharton KA. Viable mice with compound mutations in the Wnt/Dvl pathway antagonists nkd1 and nkd2. Mol Cell Biol 2007;27:4454-64.
148. Zhang M, Wang RP, Wang YY, Diao FC, Lu F, Gao D, Chen DY, Zhai ZH, Shu HB. The CXXC finger 5 protein is required for DNA damage-induced p53 activation. Sci China C Life Sci 2009;52:528-38.
149. Satoh K. Anteriorization of neural fate by inhibitor of beta-catenin and T cell factor (ICAT), a negative regulator of Wnt signaling. Proc Natl Acad Sci USA 2004;101:8017-21.
150. Voronina VA, Takemaru KI, Treuting P, Love D, Grubb BR, Hajjar AM, Adams A, Li FQ, Moon RT. Inactivation of Chibby affects function of motile airway cilia. J Cell Biol 2009;185:225-33.
151. Nishiyama M, Oshikawa K, Tsukada Y, Nakagawa T, Iemura S, Natsume T, Fan Y, Kikuchi A, Skoultchi AI, Nakayama KI. CHD8 suppresses p53-mediated apoptosis through histone H1 recruitment during early embryogenesis. Nat Cell Biol 2009;11:172-U139.